Enlivex Therapeutics Ltd., established in 2005 and based in Nes Ziona, Israel, operates as a clinical-stage biotechnology firm dedicated to macrophage reprogramming immunotherapy. The company is currently advancing Allocetra, its flagship cell-based therapeutic. This treatment is undergoing Phase II clinical evaluation for its effectiveness in addressing organ dysfunction and failure that arises from sepsis. Additionally, Allocetra is being investigated in preclinical studies for its potential application in solid tumor therapy.
Recent News & Events
Nasdaq delisting overhang and a 1-for-16 reverse split dominate near-term risk, partially offset by durable 12-month Phase I/IIa Allocetra data and Phase 2b execution progress; net near-term bias negative given listing uncertainty.
NEGATIVEOct 27, 2026
Regulatory/Delisting Notice
Nasdaq delisting notice received; company intends to appeal
Enlivex received a Nasdaq delisting determination on Oct 26, 2026 because its bid price stayed below $1.00 for 30 business days and it was ineligible for the 180-day cure period due to a prior reverse split. The company intends to request an oral hearing, which stays suspension pending the appeal, but failure to win the appeal would remove the shares from Nasdaq Capital Market and likely trigger forced selling and liquidity loss.
The company effected a 1-for-16 reverse split of its ordinary shares effective Oct 27, 2026, intended to support the Nasdaq appeal and regain bid-price compliance. Reverse splits of micro-caps are frequently followed by continued selling pressure, and the reported ratio varied across listings, adding confusion that can weigh on the stock near term.
Favorable 12-month Phase I/IIa Allocetra topline data
Enlivex reported durable 12-month responses in patients aged 64+, with 79.2% responders on Allocetra vs 47.6% on placebo (p=0.027), consistent with 3- and 6-month results and a favorable safety profile. The data support the ongoing Phase 2b program and were presented at ACR Convergence on Nov 8, 2026, providing a positive fundamental catalyst though the stock still fell sharply post-announcement.
Phase 2b Allocetra trial reaches 135 of 182 patients randomized
The company announced 135 of a planned 182 patients have been randomized and dosed in the Phase 2b trial in age-related knee osteoarthritis, with topline six-month data expected by mid-2027. This is an execution milestone rather than a data readout, so its near-term price impact is limited, though it reinforces pipeline progress.
Enlivex announced a cost reduction plan winding down non-clinical R&D, cutting workforce by approximately 60%, and reducing management and CEO salaries to extend cash runway for the Phase 2b trial. The move reduces burn but signals financial strain, a mixed signal for near-term sentiment.